1. Hybrid and SARS-CoV-2-vaccine immunity in kidney transplant recipientsResearch in context
- Author
-
Hassen Kared, Amin Alirezaylavasani, Katrine Persgård Lund, Adity Chopra, Lisa Tietze, Taissa de Matos Kasahara, Guro Løvik Goll, Gunnveig Grødeland, Mari Kaarbø, Anna Varberg Reisæter, Markus Hovd, Kristian Heldal, John Torgils Vaage, Fridtjof Lund-Johansen, Karsten Midtvedt, Anders Åsberg, and Ludvig A. Munthe
- Subjects
Kidney transplant recipients ,COVID-19 vaccination ,Anti-viral T and B cell immunity ,T cell responses ,B cell differentiation and immunity ,Medicine ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Kidney transplant recipients (KTR) are at high risk for severe COVID-19 and have demonstrated poor response to vaccination, making it unclear whether successive vaccinations offer immunity and protection. Methods: We conducted a serologically guided interventional study where KTR patients that failed to seroconvert were revaccinated and also monitored seroconversion of KTR following the Norwegian vaccination program. We analysed IgG anti-RBD Spike responses from dose 2 (n = 432) up to after the 6th (n = 37) mRNA vaccine dose. The frequency and phenotype of Spike-specific T and B cell responses were assessed in the interventional cohort after 3–4 vaccine doses (n = 30). Additionally, we evaluated the Specific T and B cell response to breakthrough infection (n = 32), measured inflammatory cytokines and broadly cross-neutralizing antibodies, and defined the incidence of COVID-19-related hospitalizations and deaths. The Norwegian KTR cohort has a male dominance (2323 males, 1297 females), PBMC were collected from 114 male and 78 female donors. Findings: After vaccine dose 3, most KTR developed Spike-specific T cell responses but had significantly reduced Spike-binding B cells and few memory cells. The B cell response included a cross-reactive subset that could bind Omicron VOC, which expanded after breakthrough infection (BTI) and gave rise to a memory IgG+ B cell response. After BTI, KTR had increased Spike-specific T cells, emergent non-Spike T and B cell responses, and a systemic inflammatory signature. Late seroconversion occurred after doses 5–6, but 38% (14/37) of KTR had no detectable immunity even after multiple vaccine doses. Interpretation: Boosting vaccination can induce Spike-specific immunity that may expand in breakthrough infections highlighting the benefit of vaccination to protect this vulnerable population. Funding: CEPI and internal funds.
- Published
- 2023
- Full Text
- View/download PDF